bioPmed core members
Versione PDF

Pomona Ricerca S.r.l.

Pomona Ricerca S.r.l.
  • Corso Einaudi, 1 – 10128 Torino

Contact Person: Massimo Ferrero
Role: CEO
Phone: +39 3466110143 Email: Website:
Founding Year: 2010
Employees: 1
Fields of business:
  • Life Sciences

Antibodies (mAbs) that neutralize human viral pathogens.

Since incorporation in 2010, Pomona Ricerca creates value from human monoclonal antibodies (mAbs) that neutralize human viral pathogens.
The company focuses on the discovery and development of human mAbs for the prophylaxis and treatment of diseases caused by Hepatitis C Viruses, Influenza Viruses and JC Virus.
The therapeutic antibodies are selected on the basis of advantages over competitor products and will be brought to clinical stages up to efficacy proof of concept.
Prof. Massimo Clementi and Roberto Burioni of the Università Vita-Salute San Raffaele are the originators of the company technology.
To date, the company activity has been financed by Angels’ Investors.

  • Diagnostica e Ricerca SAN RAFFAELE

  • Anti-idiotype monoclonal antibodies as mimotopes of the hiv gp120 antigen
  • Monoclonal antibodies capable of reacting with a plurality of influenza virus a
  • Monoclonal antibodies having homosubtype cross-neutralization properties against
  • Anti-hcv monoclonal antibody as a medicament for the therapeutic treatment and prevenction of HCV infections
  • Monoclonal antibodies as a medicament for the therapeutic and/or prophylatctic t
  • Full-length immunoglobulins of the igg isotype capable of recognizing a heterosu
  • A human monoclonal antibody against the vp1 protein of jc virus
  • Human recombinant antibody against the hepatitis C (HCV) non structural NS3 protein, nucleic acid and uses thereof
  • Human monoclonal antibody FAB fragments directed against HCVE2 glycoprotein and endowed with in vitro neutralizing activity

Piemontelifesciences company's profile: